Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
1. SLDB revealed promising interim results for SGT-003 in DMD treatment. 2. Average microdystrophin expression was recorded at 110% after 90 days. 3. Participants showed 70%-88% muscle fibers producing dystrophin, averaging 78%. 4. Adverse events were typical of AAV gene therapies, with no serious concerns. 5. Stock price rose 38.3% following positive trial data release.